Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
20th August 2020 | Bankole A. Johnson | 350,000 | Open or private sale | $1.21 | $423,500.00 |
27th March 2020 | James W. Jr. Newman | 5,000 | Open or private purchase | $1.42 | $7,100.00 |
27th March 2020 | James W. Jr. Newman | 10,000 | Open or private purchase | $1.34 | $13,400.00 |
27th March 2020 | James W. Jr. Newman | 4,644 | Open or private purchase | $1.35 | $6,269.40 |
26th March 2020 | William B. Iii Stilley | 12,652 | Open or private purchase | $1.47 | $18,598.44 |
25th March 2020 | William B. Iii Stilley | 12,348 | Open or private purchase | $1.13 | $13,953.24 |
3rd March 2020 | Joseph Truluck | 27,084 | Grant/award etc. | $0.00 | |
3rd March 2020 | William B. Iii Stilley | 54,167 | Grant/award etc. | $0.00 | |
12th December 2019 | Bankole A. Johnson | 150,000 | Open or private sale | $1.00 | $150,000.00 |
2nd October 2019 | Bankole A. Johnson | 3,187 | Grant/award etc. | $0.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial.
25th February 2021
23rd February 2021